Vangoo Capital Partners was established in China in 2008, as a wholly owned subsidiary of Ant Capital Partners, one of Japan's leading private equity investment institutions. After a management buyout in 2011, Vangoo began to operate independently. All along, Vangoo focuses on the huge market potential and the rapid growth of new enterprises in China, and closely grasps the rhythm of the nationalization of high-end technology and industrialization of innovative technology during the Chinese industrial restructuring process. Vangoo has formed its own core competiveness in the area of industrial investment.
Vangoo Capital Partners’ range of investments covers the high-growth areas of medical, Internet, consumer products, high-tech, and new energy. Cooperating with first-class international and domestic partners, Vangoo focuses on searching for and investing in the most outstanding Chinese enterprises with promising potentials. To create sustainable value, Vangoo endeavors to provide value-added professional services to target enterprises with the support of mature experiences and advanced technologies from Japan and rest of the world, helping the enterprises to reach first class level in China, or preferably the first class level by world standard.
Vangoo has already set up offices in Beijing, Tokyo, Chengdu and Suzhou.
【In March, 2008】
Vangoo Capital Limited was established in Hong Kong as the wholly owned subsidiary of Ant Capital Partners, a well-known Japanese PE firm, to focus on investments in China.
【In March, 2010】
Tianjin Vangoo-HIDEA RMB Fund, which was jointly held by Vangoo Capital Partners and TEDA, was established.
【In March, 2011】
JV fund was established with COFCO to focus on investments in Chinese agricultural field.
【In March, 2011】
Ant Capital Partners’ China team completed management buy-out of Vangoo Capital Partners, which realized its localization in China.
【In March, 2013】
JV fund, Yi Xin Kai Yuan (Suzhou) Healthcare Investment Co. Ltd., was established with CITIC Trust and Yi Xin China, the wholly owned subsidiary of the Japanese public listed company EPS, to focus on healthcare investments.